

# The N-methyl-D-aspartate (NMDA)-antagonist memantine affects training induced motor cortex plasticity: a study using transcranial magnetic stimulation

<b>Submission date</b> 06/05/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 09/05/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 15/02/2008	<b>Condition category</b> Other	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Prof Martin Tegenthoff

### Contact details

Department of Neurology  
BG-Kliniken Bergmannsheil  
Buerkle-de-la-Camp-Platz 1  
Bochum  
Germany  
44789

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

## Study information

### Scientific Title

### Study objectives

Training of a repetitive synchronised movement of two limb muscles leads to short-term plastic changes in the primary motor cortex, which can be assessed by transcranial magnetic stimulation (TMS) mapping.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Not provided at time of registration

### Study design

Randomised controlled trial

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Hospital

### Study type(s)

Treatment

### Participant information sheet

### Health condition(s) or problem(s) studied

Training induced motor cortex plasticity

### Interventions

Memantine versus placebo either given as a single dose or daily over 8 days.

### Intervention Type

Drug

### Phase

Not Specified

### Drug/device/biological/vaccine name(s)

Memantine

**Primary outcome measure**

The differential effects of different treatment regimens.

**Secondary outcome measures**

Not provided at time of registration

**Overall study start date**

01/06/1998

**Completion date**

31/01/2005

## Eligibility

**Key inclusion criteria**

Healthy subjects (adults, either sex)

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Both

**Target number of participants**

20

**Key exclusion criteria**

1. Left-handedness
2. Neurological disorders
3. Intake of central acting drugs

**Date of first enrolment**

01/06/1998

**Date of final enrolment**

31/01/2005

## Locations

**Countries of recruitment**

Germany

**Study participating centre**

Department of Neurology  
Bochum

Germany  
44789

## Sponsor information

### Organisation

BG-Kliniken Bergmannsheil (Germany) - Department of Neurology

### Sponsor details

Buerkle-de-la-Camp-Platz 1  
Bochum  
Germany  
44789

### Sponsor type

Hospital/treatment centre

### ROR

<https://ror.org/04j9bvy88>

## Funder(s)

### Funder type

Hospital/treatment centre

### Funder Name

BG-Kliniken Bergmannsheil (Germany) - Department of Neurology; main funders

### Funder Name

Merz Pharmaceuticals GmbH (Germany) - funded the measurement of the memantine serum levels

## Results and Publications

### Publication and dissemination plan

Not provided at time of registration

### Intention to publish date

### Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	Results	12/05/2005		Yes	No